Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cambridge Antibody Tech. (NasdaqNM:CATG)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | Msgs
Recent Events
Aug 31Price hit new 52-week low ($21.25)
Location
The Science Park, Cambridgeshire
Melbourne, SG8 6JJ, UK
Phone: (212) 815-2208
Fax: (212) 571-3050
Employees (last reported count): 189
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 29%
·Institutional: 0% (0% of float)
(13 institutions)
·Net Inst. Buying: 108.0K shares (+50.02%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cambridge Antibody Technology Group plc (CAT) is a biotechnology company based in the United Kingdom with an advanced platform technology for the rapid isolation of human monoclonal antibodies, which have potential to identify and treat human diseases. CAT uses its proprietary technology for drug discovery and drug development, exploiting the characteristics of antibodies both to discover and validate new disease targets and to engineer human monoclonal antibodies as treatments for human diseases. CAT's platform technology mimics aspects of the human immune system and CAT has created a library of over 100 billion distinct human monoclonal antibodies. CAT is exploiting the value of its technology to help discover and validate the role of specific targets in disease both through internal programs and by working with collaborative partners.
More from Market Guide: Expanded Business Description

Financial Summary
Cambridge Antibody Technology Group is a UK biotechnology company using proprietary technologies in human monoclonal antibodies for drug discovery and drug development. For the six months ended 3/31/01, revenue rose 4% to L6.6 million. Net loss according to U.S. GAAP decreased 12% to L10.7 million. Revenues reflect increased license fees due to amounts paid by Immunex. Loss also benefited from higher interest income due to higher average investment balances.
More from Market Guide: Significant Developments

Officers

Position
Peter Garland, Ph.D., 67Chairman
David Chiswell, Ph.D., 47CEO, Director
Jason Avery, 39Sr. VP - Bus. Alliances
Nigel Burns, Ph.D., 40Sr. VP - Preclinical Devel.
Alexander Duncan, Ph.D., 39VP - Drug Discovery
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CATGAs of 31-Aug-2001
Price and Volume
52-Week Low
on 31-Aug-2001
$21.25 
Recent Price$21.25 
52-Week High
on 11-June-2001
$38.00 
Daily Volume (10-day avg)5,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
4-Week Change-8.0%
4-Week Change
relative to S&P500
-1.5%
Share-Related Items
Market Capitalization$751.8M
Shares Outstanding35.4M
Float25.1M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$7.12 
Earnings (ttm)-$0.65 
Earnings (mrq)-$0.44 
Sales (ttm)$0.43 
Cash (mrq)$6.91 
Valuation Ratios
Price/Book (mrq)2.99 
Price/EarningsN/A 
Price/Sales (ttm)48.88 
Income Statements
Sales (ttm)$15.1M
EBITDA (ttm)-$16.8M
Income available to common (ttm)-$22.9M
Profitability
Profit Margin (ttm)-38.4%
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsSep 30
Most recent quarter31-Mar-2001
Management Effectiveness
Return on Assets (ttm)-2.99%
Return on Equity (ttm)-12.76%
Financial Strength
Current Ratio (mrq)22.55 
Debt/Equity (mrq)0 
Total Cash (mrq)$244.3M
Short Interest
As of 8-Aug-2001
Shares Short0 
Shares Short
(Prior Month)
3,000 
Daily Volume10.0K
ADR Information
Shares/ADR1
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 31-Mar-2001);   dollar amounts based on an exchange rate of 1.45 Dollars/British Pounds

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.